Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction

Who May Qualify: - Subject must be at least 19 years of age - Patients with stage C heart failure and left ventricular ejection fraction\<40% - Patients with significant coronary artery stenosis (diameter stenosis\>50% with proven inducible myocardial ischemia by invasive physiologic assessment) - Coronary artery disease is amenable for percutaneous coronary intervention (PCI) - Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written willing to sign a consent form prior to any study related procedure. Who Should NOT Join This Trial: - Myocardial infarction by universal definition within 4 weeks of randomization - Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography) - Target lesions not amenable for PCI by operators' decision - Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization - Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus - Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) - Pregnancy or breast feeding - Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment) - Unwillingness or inability to comply with the procedures described in this protocol. Always talk to your doctor about whether this trial is right for you.